Frequency and Clinical Association of NY-ESO-1 Gene Expression in Diffuse Large B-cell Lymphoma.

Background Diffuse Large B-cell Lymphoma, a heterogeneous disease, is influenced by complex network of gene interactions. In current study, we aimed to evaluate the frequency of expression and determine the expression levels of the NY-ESO-1 gene in patients with DLBCL, as well as to examine its relationship with clinical parameters and survival. Methods We analyzed NY-ESO-1 gene expression levels using real-time quantitative RT-PCR (qRT-PCR) in 112 patients with DLBCL. The associations between the expression of the NY-ESO-1 gene and the clinical variables were evaluated using the chi-square test and Fisher’s exact test. Overall survival (OS) was determined using the Kaplan-Meier method. Result The results showed that the NY-ESO-1 gene was expressed in 46.4% (52/112) of patients with DLBCL, and NY-ESO-1 gene expression was associated with clinical parameters such as LDH, clinical stage, international prognostic index (IPI) (p≤0.05). High levels of NY-ESO-1 gene expression were correlated with advanced disease stages, and the survival rates after 5.3 years of tracking were lower in the patients expressing the NY-ESO-1 gene (66.4%) than in those not expressing the gene (23.1%). Conclusion In conclusion, the expression levels of the NY-ESO-1 gene in patients with DLBCL may be of great utility for diagnosing and determining the prognosis of this disease.